Recro Pharma Reports Inducement Grants for New Staff
October 31, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting
October 10, 2017 07:00 ET
|
Recro Pharma, Inc.
IV Meloxicam 30mg Demonstrates Statistically Significant Reductions in Pain, Along with Reductions in Opioid Rescue Use and Improvements in Several Other Pain Relief Metrics Selected as a “Top 6”...
Recro Pharma to Participate in Upcoming Investor Conferences
October 05, 2017 17:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg
October 05, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Reports Inducement Grants for New Staff
September 29, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg
September 28, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017
September 05, 2017 07:00 ET
|
Recro Pharma, Inc.
IV Meloxicam 30mg Demonstrates Statistically Significant Reductions in Opioid Consumption in Overall Study Population and Important Subpopulations, Including in Patients Following Major Orthopedic...
Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development
August 21, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Reports Inducement Grants for New Staff
August 10, 2017 15:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Reports Second Quarter 2017 Financial Results
August 10, 2017 07:00 ET
|
Recro Pharma, Inc.
Reports Second Quarter 2017 Revenues of $16.9 Million NDA Submitted to U.S. FDA for IV Meloxicam MALVERN, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue...